Physician profile
David S Abend
NPI 1609806454
$952.71
in general payments reported to CMS, 2019-2025
15 companies · $48.22 in 2025
The $48.22 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2021: $248 · 2022: $264 · 2023: $113 · 2024: $125 · 2025: $48.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $285.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $247.91 | 2021 | |
| Novo Nordisk INC | $168.91 | 2022-2024 | Rybelsus, Ozempic |
| Zimmer Biomet Holdings, INC. | $104.03 | 2019 | |
| Lilly USA, LLC | $55.57 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.31 | 2022-2024 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $50.93 | 2019 | |
| Exact Sciences Corporation | $50.79 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $39.95 | 2022 | |
| Spr Therapeutics, INC | $36.81 | 2022-2023 | Sprint Pns System |
| Bayer Healthcare Pharmaceuticals INC. | $35.10 | 2025 | |
| Abbvie INC. | $33.12 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $24.97 | 2022 | |
| Curonix LLC | $22.36 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Glaxosmithkline, LLC. | $13.83 | 2022 | |
| Medicure Pharma INC. | $13.12 | 2025 | Zypitamag |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Abend listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.